HOLLISTON, Mass., March 8, 2016 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will announce results of its fourth quarter and year ended December 31, 2015 and provide business commentary after market trading hours on Thursday, March 17, 2016. A conference call to discuss the company’s fourth quarter and fiscal year 2015 results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
Participating in the call will be Jim McGorry, Chief Executive Officer, Saverio La Francesca, M.D., Executive Vice President and Chief Medical Officer and Tom McNaughton, Chief Financial Officer, of HART.
Investors can access the live conference call by dialing the following phone numbers: toll-free 877-407-8293, or international: 201-689-8349, and referencing Harvard Apparatus Regenerative Technology, Inc. An audio webcast will also be available at http://public.viavid.com/index.php?id=118656.
If you are unable to listen to the live conference call, a replay will be available within approximately 3 hours from the end of the call through 11:59pm ET on March 24, 2016 and will be accessible by dialing toll-free 877-660-6853, or toll/international 201-612-7415, and referencing conference ID “13632439". The replay will also be made available at the web link above and on the company’s web site, www.harvardapparatusregen.com.
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology (HART) is developing bioengineered organ implants utilizing the recipient’s own stem cells to treat life-threatening conditions. HART has developed and begun testing a new technology platform to create organ implants to replace diseased or damaged portions of the esophagus, trachea or bronchus to restore function.
HART’s novel “Cellframe” technology platform utilizes new scaffold materials and design, a different type and concentration of the patient’s own cells and certain other improvements to address the needs of affected patients. This new platform is currently being tested and developed further in a large-animal collaborative study with Mayo Clinic. HART is working to refine its new platform and to develop compelling data to pursue its goals of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in late 2016 to initiate clinical trials for one of its three product candidates and compassionate use implantation surgeries.
Contact:
Tom McNaughton
CFO
tmcnaughton@hartregen.com
774-233-7321
Or
Catalyst Global LLC
David Collins, Bill Jones, Helen Sun
212-924-9800
hart@catalyst-ir.com
Twitter: Investor Relations @HART_IR_Team
StockTwits: @HART_IR
Logo - http://photos.prnewswire.com/prnh/20151110/286060LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioengineered-organ-implant-developer-hart-to-host-q4-2015-conference-call-thursday-march-17th-at-500pm-et-300232228.html
SOURCE Harvard Apparatus Regenerative Technology, Inc.
